JP2009511577A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009511577A5 JP2009511577A5 JP2008535506A JP2008535506A JP2009511577A5 JP 2009511577 A5 JP2009511577 A5 JP 2009511577A5 JP 2008535506 A JP2008535506 A JP 2008535506A JP 2008535506 A JP2008535506 A JP 2008535506A JP 2009511577 A5 JP2009511577 A5 JP 2009511577A5
- Authority
- JP
- Japan
- Prior art keywords
- aqueous solution
- acid
- gastrointestinal
- group
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007864 aqueous solution Substances 0.000 claims 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 8
- 229920002472 Starch Polymers 0.000 claims 7
- 235000019698 starch Nutrition 0.000 claims 7
- 239000008107 starch Substances 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 6
- 230000002496 gastric effect Effects 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 5
- 239000012084 conversion product Substances 0.000 claims 4
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims 3
- 239000003613 bile acid Substances 0.000 claims 3
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims 3
- 229920002774 Maltodextrin Polymers 0.000 claims 2
- 239000005913 Maltodextrin Substances 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- BHTRKEVKTKCXOH-UHFFFAOYSA-N Taurochenodesoxycholsaeure Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)CC2 BHTRKEVKTKCXOH-UHFFFAOYSA-N 0.000 claims 2
- 240000008042 Zea mays Species 0.000 claims 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims 2
- 230000002411 adverse Effects 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 235000014633 carbohydrates Nutrition 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 235000005822 corn Nutrition 0.000 claims 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims 2
- 229960003964 deoxycholic acid Drugs 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- 150000004676 glycans Chemical class 0.000 claims 2
- 230000009931 harmful effect Effects 0.000 claims 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 2
- 229940035034 maltodextrin Drugs 0.000 claims 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 claims 2
- 229920001282 polysaccharide Polymers 0.000 claims 2
- 239000005017 polysaccharide Substances 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 239000006188 syrup Substances 0.000 claims 2
- 235000020357 syrup Nutrition 0.000 claims 2
- 229960001661 ursodiol Drugs 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims 1
- DXOCDBGWDZAYRQ-UHFFFAOYSA-N (3alpha,5beta)-3-Hydroxy-7-oxocholan-24 -oic acid Natural products C1CC(O)CC2CC(=O)C3C4CCC(C(CCC(O)=O)C)C4(C)CCC3C21C DXOCDBGWDZAYRQ-UHFFFAOYSA-N 0.000 claims 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 claims 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims 1
- GHCZAUBVMUEKKP-NHIHLBCISA-N 2-[[(4R)-4-[(3R,5S,7S,10S,13R,17R)-3,7-Dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]acetic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)C1C2C2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)CC1 GHCZAUBVMUEKKP-NHIHLBCISA-N 0.000 claims 1
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 claims 1
- MYYIMZRZXIQBGI-HVIRSNARSA-N 6alpha-Fluoroprednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 MYYIMZRZXIQBGI-HVIRSNARSA-N 0.000 claims 1
- DXOCDBGWDZAYRQ-AURDAFMXSA-N 7-oxolithocholic acid Chemical compound C1C[C@@H](O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)CC[C@@H]3[C@]21C DXOCDBGWDZAYRQ-AURDAFMXSA-N 0.000 claims 1
- 206010000087 Abdominal pain upper Diseases 0.000 claims 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- 239000004380 Cholic acid Substances 0.000 claims 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- VPGRYOFKCNULNK-ACXQXYJUSA-N Deoxycorticosterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 VPGRYOFKCNULNK-ACXQXYJUSA-N 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- 229920001353 Dextrin Polymers 0.000 claims 1
- 239000004375 Dextrin Substances 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 206010017886 Gastroduodenal ulcer Diseases 0.000 claims 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 claims 1
- 206010017982 Gastrointestinal necrosis Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 206010058061 Gastrointestinal oedema Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 108010007979 Glycocholic Acid Proteins 0.000 claims 1
- 229920002907 Guar gum Polymers 0.000 claims 1
- DGABKXLVXPYZII-UHFFFAOYSA-N Hyodeoxycholic acid Natural products C1C(O)C2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 DGABKXLVXPYZII-UHFFFAOYSA-N 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 claims 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims 1
- 206010061297 Mucosal erosion Diseases 0.000 claims 1
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 claims 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 1
- 208000008469 Peptic Ulcer Diseases 0.000 claims 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 claims 1
- 229960003437 aminoglutethimide Drugs 0.000 claims 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims 1
- 229960002932 anastrozole Drugs 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000012635 anticancer drug combination Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- MMIMIFULGMZVPO-UHFFFAOYSA-N benzyl 3-bromo-2,6-dinitro-5-phenylmethoxybenzoate Chemical compound [O-][N+](=O)C1=C(C(=O)OCC=2C=CC=CC=2)C([N+](=O)[O-])=C(Br)C=C1OCC1=CC=CC=C1 MMIMIFULGMZVPO-UHFFFAOYSA-N 0.000 claims 1
- 229960002537 betamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims 1
- 229960000997 bicalutamide Drugs 0.000 claims 1
- 239000003833 bile salt Substances 0.000 claims 1
- 229940093761 bile salts Drugs 0.000 claims 1
- 125000002843 carboxylic acid group Chemical group 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 229960001091 chenodeoxycholic acid Drugs 0.000 claims 1
- 125000003907 chenodeoxycholic acid group Chemical group 0.000 claims 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 1
- 229960004630 chlorambucil Drugs 0.000 claims 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims 1
- 229960002471 cholic acid Drugs 0.000 claims 1
- 235000019416 cholic acid Nutrition 0.000 claims 1
- 229940046044 combinations of antineoplastic agent Drugs 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 229960004544 cortisone Drugs 0.000 claims 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229960000684 cytarabine Drugs 0.000 claims 1
- 229960003901 dacarbazine Drugs 0.000 claims 1
- 229960004486 desoxycorticosterone acetate Drugs 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 235000019425 dextrin Nutrition 0.000 claims 1
- 229960001259 diclofenac Drugs 0.000 claims 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 1
- 229940116901 diethyldithiocarbamate Drugs 0.000 claims 1
- LMBWSYZSUOEYSN-UHFFFAOYSA-N diethyldithiocarbamic acid Chemical compound CCN(CC)C(S)=S LMBWSYZSUOEYSN-UHFFFAOYSA-N 0.000 claims 1
- 229960000616 diflunisal Drugs 0.000 claims 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 claims 1
- 229960004756 ethanol Drugs 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 229960002011 fludrocortisone Drugs 0.000 claims 1
- AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 claims 1
- 229960000618 fluprednisolone Drugs 0.000 claims 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims 1
- 229960002074 flutamide Drugs 0.000 claims 1
- 231100000029 gastro-duodenal ulcer Toxicity 0.000 claims 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 claims 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 claims 1
- 229940099347 glycocholic acid Drugs 0.000 claims 1
- 239000000665 guar gum Substances 0.000 claims 1
- 235000010417 guar gum Nutrition 0.000 claims 1
- 229960002154 guar gum Drugs 0.000 claims 1
- 229960000890 hydrocortisone Drugs 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- DKPMWHFRUGMUKF-KWXDGCAGSA-N hyocholic acid Chemical compound C([C@H]1[C@@H](O)[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 DKPMWHFRUGMUKF-KWXDGCAGSA-N 0.000 claims 1
- DGABKXLVXPYZII-SIBKNCMHSA-N hyodeoxycholic acid Chemical compound C([C@H]1[C@@H](O)C2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 DGABKXLVXPYZII-SIBKNCMHSA-N 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 229960000905 indomethacin Drugs 0.000 claims 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims 1
- 229960000991 ketoprofen Drugs 0.000 claims 1
- 229960004752 ketorolac Drugs 0.000 claims 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 1
- 229960003881 letrozole Drugs 0.000 claims 1
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 claims 1
- 229960002247 lomustine Drugs 0.000 claims 1
- 229960003464 mefenamic acid Drugs 0.000 claims 1
- 229960001929 meloxicam Drugs 0.000 claims 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 1
- 229960001428 mercaptopurine Drugs 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 229960001047 methyl salicylate Drugs 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 230000009854 mucosal lesion Effects 0.000 claims 1
- 229960002009 naproxen Drugs 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 claims 1
- 229960002653 nilutamide Drugs 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 claims 1
- 229960004662 parecoxib Drugs 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000001814 pectin Substances 0.000 claims 1
- 229920001277 pectin Polymers 0.000 claims 1
- 235000010987 pectin Nutrition 0.000 claims 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims 1
- 229960002702 piroxicam Drugs 0.000 claims 1
- 239000002244 precipitate Substances 0.000 claims 1
- 229960005205 prednisolone Drugs 0.000 claims 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- -1 pricamycin Chemical compound 0.000 claims 1
- 229960001586 procarbazine hydrochloride Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims 1
- 229960000894 sulindac Drugs 0.000 claims 1
- 229960001967 tacrolimus Drugs 0.000 claims 1
- BHTRKEVKTKCXOH-AYSJQVDDSA-N taurochenodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)C1C2C2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-AYSJQVDDSA-N 0.000 claims 1
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 claims 1
- BHTRKEVKTKCXOH-LBSADWJPSA-N tauroursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-LBSADWJPSA-N 0.000 claims 1
- 229960005294 triamcinolone Drugs 0.000 claims 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 claims 1
- GHCZAUBVMUEKKP-UHFFFAOYSA-N ursodeoxycholic acid glycine-conjugate Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)CC2 GHCZAUBVMUEKKP-UHFFFAOYSA-N 0.000 claims 1
- 125000001612 ursodeoxycholic acid group Chemical group 0.000 claims 1
- 229960002004 valdecoxib Drugs 0.000 claims 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/251,137 US7772220B2 (en) | 2004-10-15 | 2005-10-14 | Methods and compositions for reducing toxicity of a pharmaceutical compound |
| PCT/US2006/008925 WO2007044062A1 (en) | 2005-10-14 | 2006-03-10 | Bile preparations for gastrointestinal disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009511577A JP2009511577A (ja) | 2009-03-19 |
| JP2009511577A5 true JP2009511577A5 (enExample) | 2009-04-30 |
Family
ID=37943116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008535506A Pending JP2009511577A (ja) | 2005-10-14 | 2006-03-10 | 胃腸疾患用胆汁製剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7772220B2 (enExample) |
| EP (1) | EP1940428A4 (enExample) |
| JP (1) | JP2009511577A (enExample) |
| KR (1) | KR20080063401A (enExample) |
| CN (1) | CN101378769A (enExample) |
| WO (1) | WO2007044062A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7772220B2 (en) | 2004-10-15 | 2010-08-10 | Seo Hong Yoo | Methods and compositions for reducing toxicity of a pharmaceutical compound |
| US20070072828A1 (en) * | 1998-07-24 | 2007-03-29 | Yoo Seo H | Bile preparations for colorectal disorders |
| US7303768B2 (en) * | 1998-07-24 | 2007-12-04 | Seo Hong Yoo | Preparation of aqueous clear solution dosage forms with bile acids |
| US20050158408A1 (en) * | 1998-07-24 | 2005-07-21 | Yoo Seo H. | Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof |
| US7145125B2 (en) | 2003-06-23 | 2006-12-05 | Advanced Optical Technologies, Llc | Integrating chamber cone light using LED sources |
| ES2339790T3 (es) * | 2004-08-30 | 2010-05-25 | Seo Hong Yoo | Efecto neuroprotector de udca solubilizado en modelo isquemico focal. |
| DE602005027727D1 (de) * | 2004-10-15 | 2011-06-09 | Seo Hong Yoo | Zusammensetzungen zur verringerung der toxizität von cisplatin, carboplatin und oxaliplatin |
| EP1814558B1 (en) * | 2004-11-01 | 2010-12-15 | Seo Hong Yoo | Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis |
| EP2522343A1 (en) | 2006-03-28 | 2012-11-14 | Javelin Pharmaceuticals, Inc. | Formulations of Low Dose Diclofenac and Beta-Cyclodextrin |
| FR2957077B1 (fr) * | 2010-03-02 | 2012-04-13 | Univ Dauvergne Clermont I | Utilisation du riluzole pour traiter ou prevenir les effets indesirables d'agents anti-cancereux |
| CN102178685B (zh) * | 2011-03-03 | 2012-12-05 | 山东农业大学 | 牛磺鹅去氧胆酸在保护肾上腺功能上的应用 |
| JP6519219B2 (ja) * | 2015-02-19 | 2019-05-29 | 大正製薬株式会社 | リーキーガット改善剤の評価方法 |
| KR102252450B1 (ko) * | 2017-02-09 | 2021-05-14 | 주식회사 아미코젠파마 | 우르소데옥시콜산을 함유하는 시각장애 예방 또는 치료용 조성물 |
| KR102204406B1 (ko) * | 2019-01-23 | 2021-01-18 | (주)샤페론 | 타우로데옥시콜린산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 염증성 장질환 예방 또는 치료용 조성물 |
| KR102592892B1 (ko) | 2021-03-12 | 2023-10-23 | 충남대학교산학협력단 | 데속시코르티코스테론 글루코사이드를 포함하는 당뇨병 예방 또는 치료용 조성물 |
| CN115919876A (zh) * | 2022-12-29 | 2023-04-07 | 西安交通大学 | 胆汁酸衍生物在防治阿司匹林导致胃肠道损伤的药物中的应用 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4092428A (en) | 1973-11-02 | 1978-05-30 | Yamanouchi Pharmaceutical Co., Ltd. | Process of preparing stable prostaglandin E group-containing formulation |
| US4036954A (en) | 1973-11-02 | 1977-07-19 | Yamanouchi Pharmaceutical Co., Ltd. | Stable prostaglandin E group-containing formulation |
| US4113882A (en) | 1974-10-21 | 1978-09-12 | Yamanouchi Pharmaceutical Co., Ltd. | Stabilized oral prostaglandin formulation and the process for the preparation thereof |
| US4320146A (en) | 1978-03-17 | 1982-03-16 | The Johns Hopkins University | Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids |
| JPS5522616A (en) | 1978-08-04 | 1980-02-18 | Tokyo Tanabe Co Ltd | Bile acid inclusion compound and injection containing the same |
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| FR2521430A1 (fr) | 1982-02-12 | 1983-08-19 | Pan Medica | Solution aqueuse d'acide ursodesoxycholique a usages therapeutiques, son procede de preparation et application au traitement des lithiases biliaires |
| GB8313217D0 (en) | 1983-05-13 | 1983-06-22 | Glaxo Group Ltd | Pharmaceutical compositions |
| GB8417895D0 (en) | 1984-07-13 | 1984-08-15 | Marples B A | Pharmaceutical anti-fungal composition |
| JPS61171421A (ja) | 1985-08-23 | 1986-08-02 | Yamanouchi Pharmaceut Co Ltd | 安定なプロスタグランジンｅ類製剤の製造方法 |
| JPS62153220A (ja) | 1985-12-27 | 1987-07-08 | Tokyo Tanabe Co Ltd | 胆汁酸内用水剤 |
| GB8608335D0 (en) | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
| JPH0747539B2 (ja) | 1986-10-22 | 1995-05-24 | 東京田辺製薬株式会社 | 胆汁酸固形製剤 |
| JPS63243031A (ja) | 1987-03-28 | 1988-10-07 | Tokyo Tanabe Co Ltd | 胆汁酸の固形製剤 |
| HU203204B (en) | 1987-09-15 | 1991-06-28 | Sandoz Ag | Process for producing suppository containing calcitonin and taurocholic acid |
| NZ226557A (en) | 1987-10-15 | 1990-07-26 | Syntex Inc | Pharmaceutical compositions for the intranasal administration of a biologically active polypeptide in powder form and process for their preparation |
| US5342625A (en) | 1988-09-16 | 1994-08-30 | Sandoz Ltd. | Pharmaceutical compositions comprising cyclosporins |
| US5446026A (en) | 1989-08-09 | 1995-08-29 | Advanced Peptides & Biotechnology Sciences | Potent non-opiate analgesic |
| US5157022A (en) | 1989-11-22 | 1992-10-20 | Adrian Barbul | Method for reducing blood cholesterol using arginine |
| JP3165438B2 (ja) | 1990-04-04 | 2001-05-14 | バーウィンド・ファーマス―ティカル・サーヴィスィーズ・インコーポレーテッド | 水性のマルトデキストリン及びセルロースポリマーフィルムコーティング |
| US5057321A (en) | 1990-06-13 | 1991-10-15 | Alza Corporation | Dosage form comprising drug and maltodextrin |
| IT1245891B (it) | 1991-04-12 | 1994-10-25 | Alfa Wassermann Spa | Formulazioni farmaceutiche a rilascio controllato per uso orale gastroresistenti contenenti acidi biliari e loro sali. |
| IT1245889B (it) | 1991-04-12 | 1994-10-25 | Alfa Wassermann Spa | Formulazioni farmaceutiche per uso orale gastroresistenti contenenti sali di acidi biliari. |
| IT1245890B (it) | 1991-04-12 | 1994-10-25 | Alfa Wassermann Spa | Formulazioni farmaceutiche per uso orale gastroresistenti contenenti acidi biliari. |
| CH680704A5 (enExample) | 1991-05-15 | 1992-10-30 | Medichemie Ag | |
| JPH0624991A (ja) | 1991-06-20 | 1994-02-01 | Tokyo Tanabe Co Ltd | ウルソデスオキシコール酸持続性製剤 |
| HU209251B (en) | 1992-03-13 | 1994-04-28 | Synepos Ag | Process for producing stable, peroral solution drug forms with controlled release of active ingredient and comprising beta-blocking pharmacons |
| US5292534A (en) | 1992-03-25 | 1994-03-08 | Valentine Enterprises, Inc. | Sustained release composition and method utilizing xanthan gum and an active ingredient |
| GB9212511D0 (en) * | 1992-06-12 | 1992-07-22 | Cortecs Ltd | Pharmaceutical compositions |
| US5342934A (en) | 1992-06-19 | 1994-08-30 | The Trustees Of Columbia University In The City Of New York | Enantioselective receptor for amino acid derivatives, and other compounds |
| US5578304A (en) | 1992-06-22 | 1996-11-26 | Digestive Care Inc. | Compositions of digestive enzymes and salts of bile acids and process for preparation thereof |
| US5260074A (en) | 1992-06-22 | 1993-11-09 | Digestive Care Inc. | Compositions of digestive enzymes and salts of bile acids and process for preparation thereof |
| US5302400A (en) | 1992-06-22 | 1994-04-12 | Digestive Care Inc. | Preparation of gastric acid-resistant microspheres containing digestive enzymes and buffered-bile acids |
| US5977070A (en) | 1992-07-14 | 1999-11-02 | Piazza; Christin Teresa | Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis |
| IT1255968B (it) | 1992-11-27 | 1995-11-17 | Composizioni farmaceutiche contenenti acido ursodesossicolico | |
| US5346701A (en) | 1993-02-22 | 1994-09-13 | Theratech, Inc. | Transmucosal delivery of macromolecular drugs |
| EP0692487A1 (en) | 1993-03-31 | 1996-01-17 | Tokyo Tanabe Company Limited | Cholestasis ameliorant |
| LU88375A1 (fr) | 1993-07-12 | 1994-04-01 | Michel Urso Prof Medecin Et Ch | Produit énergétique stimulant la puissance virile |
| EP0773029A4 (en) | 1993-07-19 | 1997-09-03 | Tokyo Tanabe Co | HEPATITIS C VIRUS PROLIFERATION INHIBITOR |
| ATE171874T1 (de) | 1993-08-30 | 1998-10-15 | Medichemie Ag | Ursodeoxycholsäure enthaltendes arzneimittel in flüssiger darreichungsform |
| GB9405833D0 (en) | 1994-03-24 | 1994-05-11 | Pfizer Ltd | Separation of the enantiomers of amlodipine |
| US5786344A (en) * | 1994-07-05 | 1998-07-28 | Arch Development Corporation | Camptothecin drug combinations and methods with reduced side effects |
| DE4432708A1 (de) | 1994-09-14 | 1996-03-21 | Hoechst Ag | Modifizierte Gallensäuren, Verfahren zu ihrer Herstellung und ihre Verwendung |
| US5965164A (en) | 1994-10-28 | 1999-10-12 | Fuisz Technologies Ltd. | Recipient-dosage delivery system |
| US5653987A (en) | 1995-05-16 | 1997-08-05 | Modi; Pankaj | Liquid formulations for proteinic pharmaceuticals |
| US5686588A (en) | 1995-08-16 | 1997-11-11 | Yoo; Seo Hong | Amine acid salt compounds and process for the production thereof |
| US5843929A (en) | 1996-03-22 | 1998-12-01 | Mayo Foundation For Medical Education And Research | Chemoprevention of metachronous adenomatous colorectal polyps |
| EP0915703A1 (en) | 1996-03-22 | 1999-05-19 | Mayo Foundation For Medical Education And Research | Combinations of an ursodeoxycholic acid compound and a nsaid for the chemopreventive protection of the colorectum |
| US6596712B2 (en) | 1996-04-26 | 2003-07-22 | Genaera Corporation | Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities |
| US5750104A (en) | 1996-05-29 | 1998-05-12 | Digestive Care Inc. | High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith |
| US5898028A (en) | 1997-03-20 | 1999-04-27 | Novo Nordisk A/S | Method for producing powder formulation comprising an insulin |
| DE29717252U1 (de) | 1997-09-26 | 1998-02-19 | Dr. Falk Pharma GmbH, 79108 Freiburg | Arzneimittelkit aus einem Budesonid-haltigen und einem Ursodesoxycholsäure-haltigen Arzneimittel zur Behandlung von cholestatischen Lebererkrankungen |
| US6099859A (en) | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
| KR100314496B1 (ko) | 1998-05-28 | 2001-11-22 | 윤동진 | 항혈전성이 있는 헤파린 유도체, 그의 제조방법 및 용도 |
| DE19981169B4 (de) | 1998-05-28 | 2007-09-13 | Mediplex Corporation, Korea | Kovalent an Gallensäuren oder Sterine gebundenes Heparin, dessen Verwendung und diese enthaltende pharmazeutische Zusammensetzung |
| US6407117B1 (en) * | 1998-06-18 | 2002-06-18 | The George Washington University | Method of administering camptothecin compounds for the treatment of cancer with reduced side effects |
| US20070072828A1 (en) * | 1998-07-24 | 2007-03-29 | Yoo Seo H | Bile preparations for colorectal disorders |
| US7772220B2 (en) | 2004-10-15 | 2010-08-10 | Seo Hong Yoo | Methods and compositions for reducing toxicity of a pharmaceutical compound |
| US20050158408A1 (en) | 1998-07-24 | 2005-07-21 | Yoo Seo H. | Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof |
| CA2338457C (en) * | 1998-07-24 | 2009-11-17 | Seo Hong Yoo | Preparation of aqueous clear solution dosage forms with bile acids |
| US7303768B2 (en) * | 1998-07-24 | 2007-12-04 | Seo Hong Yoo | Preparation of aqueous clear solution dosage forms with bile acids |
| WO2000010552A2 (en) * | 1998-08-24 | 2000-03-02 | Global Vascular Concepts, Inc. | Use of anti-angiogenic agents for inhibiting vessel wall injury |
| US6210699B1 (en) | 1999-04-01 | 2001-04-03 | Watson Pharmaceuticals, Inc. | Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity |
| US6309663B1 (en) * | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| US7034006B2 (en) | 2000-01-10 | 2006-04-25 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of disease |
| CN100558407C (zh) | 2000-02-04 | 2009-11-11 | 柳署弘 | 制备含有胆汁酸的澄清水溶液剂型 |
| WO2002005660A2 (en) | 2000-07-18 | 2002-01-24 | The Nutrasweet Company | Drying of neotame with co-agents |
| US20030044413A1 (en) | 2000-08-15 | 2003-03-06 | Regents Of The University Of Minnesota | Methods of limiting apoptosis of cells |
| KR100368936B1 (ko) * | 2000-10-04 | 2003-01-24 | 주식회사 대웅 | 우루소데옥시콜린산을 함유한 환경호르몬 독성의 예방 및치료제 |
| AU2003261424A1 (en) | 2002-08-06 | 2004-02-23 | Nitromed, Inc. | Nitrosated and/or nitrosylated ursodeoxycholic acid compounds, compositions and methods of use |
| AU2003275495A1 (en) | 2002-11-07 | 2004-06-03 | Walter C. Low | Methods of treating injuries of the nervous system associated with hemorrhage |
| CN1770975A (zh) | 2003-04-02 | 2006-05-10 | 明尼苏达大学评议会 | 提高细胞生存能力的方法 |
| ES2339790T3 (es) * | 2004-08-30 | 2010-05-25 | Seo Hong Yoo | Efecto neuroprotector de udca solubilizado en modelo isquemico focal. |
| DE602005027727D1 (de) * | 2004-10-15 | 2011-06-09 | Seo Hong Yoo | Zusammensetzungen zur verringerung der toxizität von cisplatin, carboplatin und oxaliplatin |
| EP1814558B1 (en) | 2004-11-01 | 2010-12-15 | Seo Hong Yoo | Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis |
| EP1819318A1 (en) | 2004-11-24 | 2007-08-22 | Seo Hong Yoo | Dried forms of aqueous solubilized bile acid dosage formulation |
-
2005
- 2005-10-14 US US11/251,137 patent/US7772220B2/en not_active Expired - Fee Related
-
2006
- 2006-03-10 JP JP2008535506A patent/JP2009511577A/ja active Pending
- 2006-03-10 EP EP06738034A patent/EP1940428A4/en not_active Withdrawn
- 2006-03-10 CN CNA200680038225XA patent/CN101378769A/zh active Pending
- 2006-03-10 WO PCT/US2006/008925 patent/WO2007044062A1/en not_active Ceased
- 2006-03-10 KR KR1020087011351A patent/KR20080063401A/ko not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001236685B2 (en) | Preparation of aqueous clear solution dosage forms with bile acids | |
| US7303768B2 (en) | Preparation of aqueous clear solution dosage forms with bile acids | |
| US7932243B2 (en) | Bile preparations for gastrointestinal disorders | |
| CN101035541B (zh) | 溶解的udca在局灶缺血模型中的神经保护作用 | |
| HRP20200495T1 (hr) | Sastavi za liječenje gastrointestinalne upale | |
| US20090123390A1 (en) | Compositions for the treatment of gastrointestinal inflammation | |
| Peesa et al. | A perspective review on role of novel NSAID prodrugs in the management of acute inflammation | |
| Halter et al. | Diaphragm disease of the ascending colon: assocition with sustained-release diclofenac | |
| JP2004500378A5 (enExample) | ||
| US20060142241A1 (en) | Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis | |
| IL151132A (en) | Patridine compounds for the treatment of psoriasis | |
| CN111437444A (zh) | 一种抗肠粘连双层生物凝胶制备方法及双层生物凝胶 | |
| WO2007044062A1 (en) | Bile preparations for gastrointestinal disorders | |
| WO2006057637A1 (en) | Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof | |
| HRP20201231T1 (hr) | Kortikosteroidi, namijenjeni liječenju upalnih bolesti gastrointestinalnog sustava | |
| TW200815022A (en) | Bile preparations for colorectal disorders | |
| CN101269087A (zh) | 果胶-5-氟尿嘧啶结肠癌双靶向前体药物及制备方法 | |
| JP2019504866A5 (enExample) | ||
| EP1023314A1 (en) | Bile acid salts of metals with physiological action and the use thereof in therapy | |
| UA116312C2 (uk) | Застосування водного розчину немодифікованого с60 фулерену для терапії гострого виразкового коліту | |
| Ningren | The anti-inflammatory efficacy and adrenal suppressive effects of colon-specific glucocorticoid prodrugs on experimental colitis. | |
| CN108853170A (zh) | 口服溶解草酸钙结石的组合物 | |
| Pawar et al. | A Review On: Colon Targeted Drug Delivery System | |
| KR20090059151A (ko) | 대장 질환용 담즙 제제 | |
| Asteria et al. | Multiple enterocolic perforations and their possible association with prolonged intake of nimesulide: report of two cases |